Physician profile
Peter Vu
NPI 1861810830
$98,836.99
in general payments reported to CMS, 2019-2025
11 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2021: $34.52 · 2022: $26.47 · 2023: $180 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98,013.04 | 2019-2021 | |
| Saluda Medical Americas, INC. | $310.81 | 2025 | Evoke |
| Biotronik Nro, INC. | $133.47 | 2025 | Prospera |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Bioventus LLC | $54.79 | 2023 | Stimrouter Implantable Kit |
| Cognoa, INC. | $47.95 | 2021-2022 | |
| Amgen INC. | $26.93 | 2025 | Vectibix |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.